Medexus Pharmaceuticals Launches New Metoject® Subcutaneous 15mg Dosage for the Treatment of Rheumatoid Arthritis, Psoriasis...
May 07 2019 - 12:43PM
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”)
(TSXV: MDP, OTCQB: PDDPF), today announced the launch of a
new Metoject® Subcutaneous 15mg dose in Canada. Metoject
Subcutaneous is a pre-filled syringe of methotrexate with a
pre-attached subcutaneous needle that is approved in Canada for the
treatment of rheumatoid arthritis, psoriasis and psoriatic
arthritis.
Metoject Subcutaneous 15mg is currently
reimbursed by the Provinces of Saskatchewan, New Brunswick, Nova
Scotia and Newfoundland and Labrador through their provincial
formularies, as well as the Yukon Non-Insured Health Benefits
(NIHB) and Correctional Services Canada. As of May 1,
2019, Metoject Subcutaneous 15 mg is reimbursed in the Province of
Ontario by the Ontario Drug Benefit Program (ODB). Metoject
Subcutaneous 15 mg dose is in addition to the dosage strengths of
17.5mg, 20mg, 22.5mg and 25mg currently offered in Canada by
Medexus.
Ken d’Entremont, Chief Executive Officer of
Medexus, commented, “The new 15mg dose of Metoject Subcutaneous is
an important addition to the Metoject line in Canada, as it gives
physicians more flexibility to accurately prescribe an appropriate
strength for their patients, and offers patients a more convenient
and comfortable option. We expect this dose to be a significant
portion of our Metoject volume going forward.”
About Medexus
Medexus is a leading specialty pharmaceutical
company with a strong North American commercial platform. The
Company’s vision is to provide the best healthcare products to
healthcare professionals and patients, through our core values of
Quality, Innovation, Customer Service and Teamwork. Medexus
Pharmaceuticals is focused on the therapeutic areas of auto-immune
disease and pediatrics. The leading products are Rasuvo and
Metoject, a unique formulation of methotrexate (auto-pen and
pre-filled syringe) designed to treat rheumatoid arthritis and
other auto-immune diseases; and Rupall, an innovative prescription
allergy medication with a unique mode of action.
For more information, please
contact:
Ken d’Entremont, Chief Executive OfficerMedexus
Pharmaceuticals Inc.Tel.: 905-676-0003E-mail:
ken.dentremont@medexus.com
Roland Boivin, Chief Financial OfficerMedexus
Pharmaceuticals Inc.Tel.: 514-762-2626 ext. 202E-mail:
roland.boivin@medexus.com
Investor Relations (U.S.):Crescendo
Communications, LLCTel: +1-212-671-1020Email:
ACST@crescendo-ir.com
Investor Relations (Canada):Frank CandidoDirect
Financial Strategies and Communication Inc.Tel: 514-969-5530E-mail:
frank.candido@medexus.com
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
READER ADVISORIES
Forward Looking Statements This press release
contains “forward-looking information” within the meaning of
applicable securities legislation. Forward-looking information
includes, but is not limited to, statements with respect to future
business operation and results, including with respect to future
profitability and financial results. All statements, other than of
historical fact, that address activities, events or developments
that the Company believes, expects or anticipates will or may occur
in the future are forward-looking statements. Forward-looking
statements are generally identifiable by use of the words “may”,
“will”, “should”, “continue”, “expect”, “anticipate”, “estimate”,
“believe”, “intend”, “plan” or “project” or the negative of these
words or other variations on these words or comparable terminology.
Forward-looking statements are subject to a number of risks and
uncertainties, many of which are beyond the Company's ability to
control or predict, that may cause the actual results of the
Company to differ materially from those discussed in the
forward-looking statements. Factors that could cause actual results
or events to differ materially from current expectations include,
among other things, without limitation, the risk that the
operations of the Company, Medac Pharma, Inc. and Medexus Inc. will
not be integrated successfully, the Company's inability to
commercialize products in the medac GmbH portfolio, including but
not limited to the Metoject® Subcutaneous 15mg dose, or its
inability to realize upon potential opportunities presented
thereby, as well as other risks applicable to the Company disclosed
in the Company's public disclosure record on file with the relevant
securities regulatory authorities. Although Company believes that
the expectations and assumptions on which such forward-looking
information is based are reasonable, undue reliance should not be
placed on the forward-looking information because Company can give
no assurance that they will prove to be correct. Since
forward-looking information addresses future events and conditions,
by its very nature they involve inherent risks and uncertainties.
The Company’s actual results, performance or achievement could
differ materially from those expressed in, or implied by, the
forward-looking information and, accordingly, no assurance can be
given that any of the events anticipated by the forward-looking
information will transpire or occur, or if any of them do so, what
benefits that Company will derive therefrom. Management has
included the above summary of assumptions and risks related to
forward-looking information provided in this press release in order
to provide securityholders with a more complete perspective on the
Company's future operations and such information may not be
appropriate for other purposes. Readers should not place undue
reliance on forward-looking statements. Readers are cautioned that
the foregoing lists of factors are not exhaustive. Additional
information on these and other factors that could affect the
Company's operations or financial results are included in reports
on file with applicable securities regulatory authorities and may
be accessed through the SEDAR website (www.sedar.com). The
forward-looking statements included in this news release are made
as of the date of this news release and the Company does not
undertake an obligation to publicly update such forward-looking
statements to reflect new information, subsequent events or
otherwise unless required by applicable securities legislation.
Medexus Pharmaceuticals (TSXV:MDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medexus Pharmaceuticals (TSXV:MDP)
Historical Stock Chart
From Jul 2023 to Jul 2024